CNDAC is primarily utilized in the development of anticancer drugs, particularly in the synthesis of nucleoside analogs. These analogs are designed to inhibit the replication of cancer cells by incorporating into DNA and disrupting its synthesis. This mechanism makes CNDAC a valuable component in the creation of chemotherapeutic agents targeting various types of cancers. Its ability to induce DNA damage selectively in cancer cells enhances its effectiveness in reducing tumor growth while minimizing harm to healthy tissues. Ongoing research continues to explore its potential in combination therapies and its role in improving treatment outcomes for cancer patients.